Letter: Co-trimoxazole resistance
Related Articles
- Cotrimoxazole prophylaxis for infants exposed to HIV infection. Graham, Stephen M. // Bulletin of the World Health Organization;Apr2004, Vol. 82 Issue 4, p297
Focuses on the risks and benefits of implementing guidelines on the use of cotrimoxazole prophylaxis for prevention of HIV-related infections in infants in Africa. Toxicity of cotrimoxazole; Improvement of diagnosis for HIV infection; Reduction of the duration of prophylaxis and risk of...
- Cotrimoxazole myelotoxicity in hematopoietic SCT recipients: time for reappraisal. Fontanet, A.; Chalandon, Y.; Roosnek, E.; Mohty, B.; Passweg, J. R. // Bone Marrow Transplantation;Sep2011, Vol. 46 Issue 9, p1272
A letter to the editor is presented which discusses cotrimoxazole myelotoxicity in recipients of hematopoietic stem cell transplantation (HSCT).
- Susceptibility of Gra Negative Bacteria to Cotrimoxazole in Specimens Sent to the Laboratory of Shahidbeheshti Hospital. Sharif, Alireza; Sharif, Mohammad Reza; Alizargar, Javad // Middle East Journal of Scientific Research;2014, Vol. 21 Issue 3, p440
Antibiotic resistance represents a complex dynamics problem, results in increasing cost of treatment, morbidity and mortality. As the use of Cotrimoxazole increases in the treatment of Gram-negative infections, pattern of infection and bacterial susceptibility of Gram-negative bacteria to...
- Refractory Craniofacial Actinomycetoma Due to Streptomyces somaliensis That Required Salvage Therapy with Amikacin and Imipenem. Baril, Laurence; Boiron, Patrick; Manceron, Véronique; Ely, Seydina Oumar Ould; Jamet, Pierre; Favre, Estelle; Caumes, Eric; Bricaire, Francois // Clinical Infectious Diseases;8/1/1999, Vol. 29 Issue 2, p460
Presents a case of mycetoma of the face and skull due to Streptomyces (S.) somaliensis resistant to co-trimoxazole clinically and in vitro. Initial therapy for craniofacial mycetoma; Resistance and susceptibility of S. somaliensis to several drugs; Cranial images of a patient with craniofacial...
- Use of anitbiotics. Reeves, D.S.; Bint, A.J.; Bullock, D.W. // British Medical Journal;8/5/1978, Vol. 2 Issue 6134, p410
Examines the effectiveness of antibacterial agents sulphonamides, co-trimoxazole and tetracyclines. Differences between sulfonamide derivatives; Mode of action and resistance trimoxazole; Adverse reactions to tetracyclines.
- Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study. Goldberg, Elad; Paul, Mical; Talker, Olga; Samra, Zmira; Raskin, Maria; Hazzan, Rawi; Leibovici, Leonard; Bishara, Jihad // Journal of Antimicrobial Chemotherapy (JAC);Aug2010, Vol. 65 Issue 8, p1779
Objectives: To evaluate the efficacy and safety of co-trimoxazole versus that of vancomycin in adults with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia.
- Cotrimoxazole: Drug resistance: case report. // Reactions Weekly;Jun2019, Vol. 1756 Issue 1, p118
A case study of a 40-year-old man is presented, who developed resistance following administration of cotrimoxazole for infection with Stenotrophomonasmaltophilia (SM).
- Therapeutic Challenge for Isospora belli Enteritis in an AIDS Patient Who Developed Lyell Syndrome after Co-Trimoxazole Therapy. Romeu, Joan; Clotet, Bonaventura; Tural, Cristina; Carles, Joan; Foz, Marius // American Journal of Gastroenterology;Feb1989, Vol. 84 Issue 2, p207
Presents a letter to the editor about an AIDS patient with Isospora belli enteritis who developed a Lyell syndrome secondary to treatment with co-trimoxazole.
- PCP Prophylaxis in Perinatally HIV-Exposed Infant. Shahid, Sukhbir Kaur // Indian Pediatrics;Nov2008, Vol. 45 Issue 11, p939
A letter to the editor is presented about the recommendations for cotrimoxazole Pneumocystis carinii pneumonia (PCP) prophylaxis in perinatally human immunodeficiency virus (HIV)-exposed babies.
- PCP Prophylaxis in Perinatally HIV-Exposed Infant. Tullu, Milind S. // Indian Pediatrics;Nov2008, Vol. 45 Issue 11, p939
A response to a letter to the editor about the recommendations for cotrimoxazole Pneumocystis carinii pneumonia (PCP) prophylaxis in perinatally human immunodeficiency virus (HIV)-exposed babies is presented.
